MARKET

MDCX

MDCX

Medicus Pharma Ltd
NASDAQ
0.3873
-0.2906
-42.87%
After Hours: 0.3820 -0.0053 -1.37% 19:59 03/06 EST
OPEN
0.5866
PREV CLOSE
0.6779
HIGH
0.5990
LOW
0.3700
VOLUME
16.51M
TURNOVER
--
52 WEEK HIGH
8.94
52 WEEK LOW
0.3700
MARKET CAP
9.73M
P/E (TTM)
-0.1963
1D
5D
1M
3M
1Y
5Y
1D
New to The Street Broadcasts Tonight on Bloomberg Television at 6:30 PM EST - Shows 736, 737 and 738 Air Across the U.S., Latin America and MENA
Barchart · 1d ago
Medicus Pharma Raises Equity Financing, Reduces Yorkville Debenture
TipRanks · 1d ago
Medicus Pharma Sells 4.47M Shares to Yorkville for $3.85M Under SEPA
Reuters · 1d ago
Maxim Group Reaffirms Their Buy Rating on Medicus Pharma Ltd (MDCX)
TipRanks · 1d ago
Medicus Pharma Posts Strong Phase 2 Data for Microneedle Basal Cell Carcinoma Therapy
TipRanks · 2d ago
Medicus Pharma announces results from Phase 2 study of D-MNA
TipRanks · 2d ago
Medicus Pharma Reports Phase 2 SkinJect D-MNA Data Showing 73% Clinical Clearance in Basal Cell Carcinoma
Reuters · 3d ago
MEDICUS PHARMA LTD - EXPECTS END-OF-PHASE 2 FDA MEETING IN FIRST HALF OF 2026
Reuters · 3d ago
More
About MDCX
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. SkinJect Inc., a wholly owned subsidiary of the Company, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. It is conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. It has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the UAE. Its subsidiary, Antev Limited, is a late clinical stage biotech company, developing Teverelix, a GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse episodes due to enlarged prostate.

Webull offers Medicus Pharma Ltd stock information, including NASDAQ: MDCX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDCX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MDCX stock methods without spending real money on the virtual paper trading platform.